Mesoblast announced that it is launching the first allogeneic cell therapy to ever achieve full approval in Japan, a mesenchymal stem cell (MSC) product TEMCELL® HS Inj. The product will be used for the treatment of acute graft versus host disease (aGVHD), sold through Mesoblast’s Japanese licensee, JCR Pharmaceuticals.
To learn more, read the full press release from Mesoblast below. [Read more…]